In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent artificial intelligence (AI) initiatives in the news. She then welcomes Jane Hermansen, manager of Mayo Clinic Laboratories’ Outreach Program, to discuss the value of outreach programs in strengthening laboratories and supporting broader healthcare systems.

• AI’s potential and limitations (00:01): Learn what’s next and the challenges that remain as Drs. Pritt and Morice discuss recent stories about AI in healthcare.
• Value of outreach (07:30): Discover how laboratory outreach programs support their organizations, delivering benefits that range from improved patient care to lower testing costs and growth across health system service lines.
• Getting the most from outreach (15:54): Learn the three most important things lab leaders can do to get the greatest value from their outreach program.
• The future of outreach (17:53): Get insights on how outreach may evolve in the coming years as healthcare changes.

Resources

• Fortune: A decade after the ‘Godfather of AI’ said radiologists are obsolete, salaries are $571K and growing
• “Answers From the Lab” podcast: Digital Advances: What's Next for Clinical Diagnostics?
• Personalized pathways through digital diagnostics: A Q&A with Chris Garcia, M.D.
• Outreach & Business Solutions
• Own your lab: Hospital-owned labs generate long-term financial and clinical value
• Leveraging the Laboratory Conference

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent industry news and how clinical diagnostics are powering more personalized care. Together, they explore:

• Point-of-care testing in outbreak response (00:29): Hear about the potential and limitations of point-of-care testing during disease outbreaks.
• A rare type of Lyme disease (02:46): Learn about the spread of the second known pathogen to cause Lyme disease in the U.S.
• The evolution of AI (04:50): Dr. Morice shares insights from a recent conference, highlighting the shift from discussing artificial intelligence’s potential to scaling real-world clinical applications.
• Personalized medicine and diagnostics (06:07): Discover how clinical diagnostics are driving personalized medicine and how data will shape its future.

Resources

• Four ways diagnostics are driving more personalized care
• "Answers From the Lab" podcast: Advancing Precision Medicine Through Therapeutic Tests
• "Answers From the Lab" podcast: Risks Increase as Ticks, Mosquitoes, and Similar Vectors Spread
• Therapeutics testing: Discover the differences

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.

• PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.
• Policy changes influencing diagnostics (04:09): Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field.
• Pharmacogenomic tests improving cancer care (08:14): Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing.

Resources

• CMS: CLFS & PAMA reporting and resources
• Precision Oncology Therapeutics: Personalized cancer treatment
• Answers From the Lab: Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
• Answers From the Lab: Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, speaks with William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, about Ebola, hantavirus and takeaways from a recent healthcare conference. Later, she welcomes Elli Theel, Ph.D., a microbiologist in Mayo Clinic’s Department of Laboratory Medicine and Pathology, to explore vector-borne diseases.

• Top industry topics (00:04): Dr. Morice highlights key topics from a recent major healthcare conference, including AI and payment reform.
• Infectious diseases in the news (04:04): Overview of hantavirus, Ebola, and why laboratory medicine is important during outbreaks.
• Growing prevalence of vector-borne diseases (06:48): Insights on the growing prevalence of vector-borne diseases.
• Testing options (09:45): Understand the different types of testing available for pathogens and when it is best to use each one.
• Innovation and discovery (17:05): Discover emerging pathogens and advances in detection.
• Protect yourself (19:41): Learn easy ways to protect yourself and your family from vector-borne diseases.

Note: Information in this post was accurate at the time of its posting.

Resources

• Forbes: Is hantavirus an emerging threat? What you need to know
• Vector-borne diseases by geographic region
• Vector-borne diseases: The right tests for detection and diagnosis
• Learn the ABCs of ticks

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes Brad Karon, M.D., Ph.D., division chair for Mayo Clinic's Clinical Core Laboratory Services and a member of the laboratory and pathologist stewardship team, to discuss laboratory stewardship strategies and why they matter.

• Why lab stewardship is important (00:44): How improved test utilization benefits laboratories, healthcare systems, and patients.
• Strategies for promoting lab stewardship (03:40): Proven approaches for improving appropriate test utilization.
• How industry disrupters will change stewardship efforts (09:33): How artificial intelligence and other emerging disruptors may reshape lab stewardship efforts.

Note: Information in this post was accurate at the time of its posting.

Resources

• Froedtert and the Medical College of Wisconsin: Promoting laboratory stewardship through clinical decision support
• Five steps to optimizing your outreach test menu
• Hospital-owned labs generate long-term financial and clinical value

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to reflect on the essential role of laboratory medicine during National Medical Laboratory Professionals Week. Dr. Pritt also welcomes Julia Lehman, M.D., a dermatologist and dermatopathologist at Mayo Clinic, to discuss innovative diagnostic tests for autoimmune diseases affecting the skin.

• Laboratory medicine’s expanding role (00:15): Learn how laboratory medicine touches nearly every aspect of healthcare — and why its importance will continue to grow with the integration of AI.
• An inspiring patient story (05:22): Hear how a young patient with a rare disease is able to pursue her passion for dance thanks to advances in laboratory medicine.
• Advances in testing for autoimmune blistering diseases (07:29): Discover how novel diagnostic tests are helping clinicians better tailor treatment for patients with complex skin conditions.

Note: Information in this post was accurate at the time of its posting.

Resources

• Immunodermatology: Unmatched testing expertise
• A family's journey with an ultra-rare disease: Isabel the incredible

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent news and updates. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories’ chief digital innovation officer, to explore digital advances in clinical diagnostics.

• AI systems for healthcare guidance (00:36): Learn how patients and consumers are using AI tools to better understand their health information.
• Diagnostic’s digital innovation journey (07:43): Explore the evolution of digital advances, their impact on care today, and what lies ahead.
• Guidance for selecting new tools (20:51): Gain practical guidance on selecting new digital tools in the laboratory.

Note: Information in this post was accurate at the time of its posting.

Resources

• From Intake to Interpretation: How AI Assists Lab Teams Today
• Making the Promise of AI a Reality in Laboratory Medicine and Pathology

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to share industry updates and Mayo Clinic’s test development success in 2025. Later, Dr. Pritt welcomes Janelle Santos, M.D., a maternal-fetal medicine specialist at Mayo Clinic, to discuss how she uses a preeclampsia test to care for her patients.

• Public policy insights for 2026 (00:34): Dr. Bill Morice shares insights on reimbursement and AI-related policy developments following an association meeting in Washington, D.C.
• An unprecedented year for test development (04:45): Discover how Mayo Clinic’s record year for test development delivers value to Mayo Clinic’s patients and Mayo Clinic Laboratories’ clients.
• Novel preeclampsia testing (08:13): Learn how new clinical testing helps physicians improve outcomes for women at risk for preeclampsia and their babies.

Note: Information in this post was accurate at the time of its posting.

Resources

• 4 steps to establishing a new approach to innovation
• Innovation beyond the bench: Translating science into better diagnostics and outcomes
• Preeclampsia: Empowering confident decision-making through preeclampsia risk assessment
• Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D.
• Preeclampsia sFlt-1/PIGF Ratio, Serum (Mayo ID: PERA)